NEW YORK, N.Y. – The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Week of January 26:
Ascendis Pharma A/S – Denmark, 5 million ordinary shares, priced, $16 to $18, managed by BofA Merrill Lynch, and Leerink Partners. Proposed Nasdaq symbol ASND. Business: Developing long-acting treatments for growth hormone deficiency.
Avinger Inc. – Redwood City, Calif., 4.6 million shares, priced $12 to $14, managed by Canaccord Genuity, and Cowen & Co. Proposed Nasdaq symbol AVGR. Business: Sells an image-guided, catheter-based system to treat peripheral arterial disease.
Entellus Medical Inc. – Plymouth, Minn., 4.4 million shares, priced $15 to $17, managed by BofA Merrill Lynch, and Piper Jaffray. Proposed Nasdaq symbol ENTL. Business: Sells a minimally invasive treatment to open obstructed sinus pathways.
Flex Pharma Inc. – Boston, 4.6 million shares, priced $12 to $14, managed by Jefferies, and Piper Jaffray. Proposed Nasdaq symbol FLKS. Business: Developing dietary supplements for the treatment of muscle cramps and spasms.
Infraredx Inc. – Burlington, Mass., 4 million shares, priced, $13 to $15, managed by RBC Capital Markets, Canaccord Genuity, and BMO Capital Markets. Proposed Nasdaq symbol REDX. Business: Markets a FDA-cleared optical catheter that identifies lipid core coronary plaques.
InfraREIT Inc. – Dallas, 20 million shares, priced $19 to $21, managed by BofA Merrill Lynch, and Citigroup. Proposed NYSE symbol HIFR. Business: REIT formed to own electric transmission and distribution assets in Texas.
Presbia plc – Dublin, Ireland, 4.2 ordinary shares, priced $11 to $13, managed by Jefferies. Proposed Nasdaq symbol LENS. Business: Sells surgically implanted lenses to correct age-related vision loss.
Shake Shack Inc. – New York, 5 million class A shares, priced $14 to $16, managed by J.P. Morgan, and Morgan Stanley. Proposed NYSE symbol SHAK. Business: Fast-casual burger chain with 36 U.S. and 27 international locations.
Spark Therapeutics Inc. – Philadelphia, 5.5 million shares, priced $15 to $17, managed by J.P. Morgan, and Credit Suisse. Proposed Nasdaq symbol ONCE. Business: Developing gene therapy treatments for retinal dystrophies and hematologic disorders.
Tracon Pharmaceuticals Inc. – San Diego, 3.6 million shares, priced, $12 to $14, managed by Wells Fargo, and Stifel. Proposed Nasdaq symbol TCON. Business: Developing antibodies to treat cancer, AMD and fibrotic diseases.
Zosano Pharma Corp. – Fremont, Calif., 3 million shares, priced, $10 to $12, managed by Ladenburg Thalmann, and Roth Capital. Proposed Nasdaq Capital Market symbol ZSAN. Business: Developing a transdermal formulation of an approved osteoporosis treatment. Previously postponed in July 2014.